Compare Franklin Resources, Inc. (BEN) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Franklin Resources, Inc. vs Quest Diagnostics Inc — how do they compare? Franklin Resources, Inc. trades at $33.59 (market cap $16.95B), while Quest Diagnostics Inc trades at $237.87 (market cap $26.21B). The key difference: Quest Diagnostics Inc is the larger of the two by market cap, and Franklin Resources, Inc. pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BEN | DGX | |
|---|---|---|
Market Cap | $16.95B | $26.21B |
Sector | Financials | Health |
52-Week High | $35.77 | $238.50 |
52-Week Low | $21.18 | $173.49 |
Enterprise Value | $29.90B | $31.97B |
Dividend Yield | 3.96% | 1.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Franklin Resources (BEN) trades at $33.56, up 0.12% on the day, with a bullish technical signal and consistent earnings beats. The company reported record AUM of $1.80 trillion as of July 31, 2026, driven by strong inflows and diversification efforts. Valuation ratios include a P/E of 22.69 and P/S of 1.85, while profitability shows a net income margin of 8.72%.
The outlook is positive with analyst consensus price target of $36.50, though risks include volatile cash flows and competitive pressures. Upside potential hinges on sustained AUM growth and margin expansion, while investor sentiment is mixed with 59% hold ratings amid recent institutional selling.
Quest Diagnostics (DGX) trades at $237.63, down slightly by 0.3% today, but maintains strong momentum with three consecutive quarterly earnings beats and a raised 2026 outlook. The stock shows bullish technical signals with moving averages supporting upward trends, while fundamentals reveal solid revenue growth to $11.04 billion in 2025 and improving profit margins. Recent news highlights surging testing demand and AI implementation driving operational efficiency.
DGX presents a favorable investment case with analyst consensus price target of $249.50 offering 5% upside potential. Strong testing demand, strategic partnerships, and earnings momentum support growth, though elevated debt levels and margin pressures from lower-margin deals pose moderate risks. The stock's current valuation at 25.21 P/E appears reasonable given growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Franklin Resources, Inc.
Franklin Resources provides investment services for individual and institutional investors. At the end of August 2022, Franklin had $1.388 trillion in managed assets, composed primarily of equity (32%), fixed-income (38%), multi-asset/balanced (10%) funds, alternatives (16%), and money market funds (4%). Distribution tends to be weighted more toward retail investors (49% of AUM) investors, as opposed to institutional (49%) and high-net-worth (2%) clients. Franklin is also one of the more global firms of the U.S.-based asset managers with more than 35% of its AUM invested in global/international strategies and 25% of managed assets sourced from clients domiciled outside the United States.
Read more on BEN →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
